Search
Quinupristin
go.drugbank.com/drugs/DB01369ApprovedThe combination of the two components acts synergistically and is more effective in vitro than each component alone. … Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
Fasinumab
go.drugbank.com/drugs/DB12157Investigational[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e
Categories: Analgesics, Non-NarcoticArrhenatherum elatius pollen
go.drugbank.com/drugs/DB10879ApprovedArrhenatherum elatius pollen is the pollen of the Arrhenatherum elatius plant. Arrhenatherum elatius pollen is mainly used in allergenic testing.
Mixtures: Mixture of Standardized and Non-Standardized Coastal Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalIt has been investigated for the treatment of Rheumatoid Arthritis (phase II). … CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalZunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.
Categories: Experimental Unapproved Treatments for COVID-19NUC B1000
go.drugbank.com/drugs/DB05242Experimental[F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.
DTS-201
go.drugbank.com/drugs/DB06071ExperimentalDTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which
EGEN-001
go.drugbank.com/drugs/DB05953InvestigationalEGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
INO-4800
go.drugbank.com/drugs/DB15693InvestigationalINO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. … [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.
Categories: Experimental Unapproved Treatments for COVID-19Synonyms: INO-4800 DNA Coronavirus Vaccine